Brain Health

The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.

If approved, the test could provide more timely and accurate diagnosis, hopefully mitigating the impact of Alzheimer disease (AD) on individuals and the community.

The study is the first of 5 studies co-published by AYR Wellness and LECOM and showcases improvements in physical, social, and mental well-being with minimal AEs.

The campaign for National Stress Awareness Month in April is under way.

Aged mice displayed improvements in their spatial cognition, short-term memory, and muscle durability.

A study about modifiable risk factors on a “weak spot” in the brain network found that diabetes, pollution, and alcohol were most likely to contribute to dementia disorders.

The recent ODD for the utidelone injectable could offer another treatment option for patients with BCBM.

The results displayed a dramatic reduction in the individuals’ tumors within days after single treatment.

Case reports have shown a potential association with adverse psychological effects.

The findings also indicated that individuals who experienced significant adverse events in childhood were approximately 17% more likely to experience adverse events in adulthood.

The device conducts blood biomarker tests that accurately diagnose amyloid pathology and can assist in diagnosing Alzheimer disease in patients with cognitive impairment.

The CBT-based intervention, compared with routine pregnancy care, demonstrated reductions of 81% and 74% for depression and anxiety, respectively.

Using deep brain simulation, study authors identified networks in the brain that can be used to better treat Parkinson disease, dystonia, Tourette syndrome, and OCD.

Hypomyelination with atrophy of the basal ganglia and cerebellum is the most severe form of TUBB4A leukodystrophy that currently has no curative treatment.

The dynamic reconfigurations in individuals taking antidepressant were higher than in non-users and controls, with no significant differences between those with MDD or an anxiety disorder.

Sustained cognitive improvement is likely a result of lower inflammation, remission of comorbidities, higher physical activity, and better mood.

The authors emphasize that further research on a diverse population that focuses on the role of duration and lifestyle choices and neuroinflammatory markers should be performed.

Despite the tool’s ability to predict efficacy of sertraline in patients with major depressive disorder, the investigators note that future research will seek to improve the algorithm.

The study authors noted that further research with larger populations should be conducted to boost the reliability and generalizability of the results.

Patients who took a multivitamin for 2 to 3 years showed improvements in global cognition and episodic memory compared with placebo.

The study authors note that to effectively implement tools, processes, and strategies within practices, the stigma surrounding cognitive impairment must be addressed.

The study used optogenetics to repeatedly activate and inhibit cells, revealing rapid changes in a protein called pyruvate dehydrogenase when cells were inhibited.

Migraines are not a one-size-fits-all condition, and there is no one-size-fits-all solution.

New sentences that had different linguistic properties than traditional sentences drove brain activity, according to the study authors.

The results from the preclinical trial can provide a new method of measuring dietary sources of nutrients in the tissue, but further research is needed to confirm the findings in the human brain.

Compared to placebo, a daily multivitamin showed consistent benefits in global cognition and episodic memory across a clinical trial and meta-analysis of 3 trials.

Benzodiazepines have proven effective in managing anxiety and insomnia, but they heighten risk of falls, cognitive impairment, functional decline, and mortality among older adults.

However, cognitive performance was not significantly worse than patients hospitalized for other conditions of a similar severity.

These patients have slow brain wave activity during wakefulness, which can reduce the firing of nerve cells to protect against the pathology of epilepsy.

Despite nearly one-third of reversible dementia cases being drug induced, cognitive safety is a neglected aspect of clinical trials.